medigraphic.com
ISSN 0016-3813 (Impreso)

2017, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2017; 153 (3)


Conferencia Dr. Ignacio Chávez: Caminando hacia una medicina molecular

García-Sáinz JA

Idioma: Español
Referencias bibliográficas: 48
Paginas: 379-382
Archivo PDF: 71.86 Kb.


FRAGMENTO

El solo nombre del Dr. Ignacio Chávez y la calidad académica de los que me han precedido me hacen sentir emocionado, consciente de que me encuentro sobre los hombros de grandes aportadores a nuestra medicina. La medicina se ocupa del hombre en una forma integral, como entidad biopsicosocial, y es por ello, como el hombre mismo, muy amplia y compleja. Los aspectos moleculares son solamente una pequeña faceta del gran diamante que es la medicina, y yo hablaré de una pequeña fracción de ella. Tataré de convencerlos de que, a pesar del reduccionismo, mantiene contacto con las grandes preguntas de la medicina. Parafraseando al poeta León Felipe diré que «todo el ritmo de la vida pasa por esa ventana... y la muerte también pasa». Usaré como hilo conductor mi trabajo sobre receptores, particularmente los adrenérgicos, señalando algunos cambios generales que han ocurrido en los 46 años que han transcurrido desde que ingresé a la facultad de medicina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Langley JN. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol. 1905;33:374-413.

  2. Robert L, Labat-Robert J, Robert AM. Receptors and aging: dedicated to the memory of Paul Ehrlich for the 100th anniversary of his Nobel Prize. Arch Gerontol Geriatr. 2010;51:260-3.

  3. Butcher RW, Robison GA. An appreciation of Earl Sutherland. Metabolism. 1975;24:237-40.

  4. Raju TN. The Nobel chronicles. 1971: Earl Wilbur Sutherland, Jr. (1915- 74). Lancet. 1999;354:961.

  5. Ahlquist RP. Historical perspective. Classification of adrenoreceptors. J Auton Pharmacol. 1980;1:101-6.

  6. Oliver G, Schafer EA. The physiological effects of extracts of the suprarenal capsules. J Physiol. 1895;18:230-76.

  7. Abel JJ, Crawford AC. On the blood-pressure raising constituent of the suprarenal capsule. Bull Johns Hopkins Hosp. 1897;7:151.

  8. Takamine J. The isolation of the active principle of the suprarenal gland. J Physiol. 1901;27:30p-1p.

  9. García-Sainz JA. Adrenaline and its receptors: one hundred years of research. Arch Med Res. 1995;26:205-12.

  10. Insel PA. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors − evolving concepts and clinical implications. N Engl J Med. 1996;334:580-5.

  11. Frishman WH. Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology. Am J Med. 2008;121:933-4.

  12. Hoffman BB. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. En: Hardman JGL, Gilman AG, editores. Goodman and Gilman’s. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 215-68.

  13. Berthelsen S, Pettinger WA. A functional basis for classification of alpha- adrenergic receptors. Life Sci. 1977;21:595-606.

  14. Fain JN, García-Sáinz JA. Role of phosphatidylinositol turnover in alpha 1 and of adenylate cyclase inhibition in alpha 2 effects of catecholamines. Life Sci. 1980;26:1183-94.

  15. Burns TW, Langley PE, Terry BE, et al. Pharmacological characterizations of adrenergic receptors in human adipocytes. J Clin Invest. 1981;67:467-75.

  16. Garcia-Sainz JA, Boyer JL, Michel T, et al. Effect of pertussis toxin on alpha 2-adrenoceptors: decreased formation of the high-affinity state for agonists. FEBS Lett. 1984;172:95-8.

  17. García-Sáinz JA, Hoffman BB, Li SY, et al. Role of alpha 1 adrenoceptors in the turnover of phosphatidylinositol and of alpha 2 adrenoceptors in the regulation of cyclic AMP accumulation in hamster adipocytes. Life Sci. 1980;27:953-61.

  18. Boyer JL, Garcia A, Posadas C, et al. Differential effect of pertussis toxin on the affinity state for agonists of renal alpha 1- and alpha 2-adrenoceptors. J Biol Chem. 1984;259:8076-9.

  19. García-Sáinz JA. Decreased sensitivity to alpha 2 adrenergic amines, adenosine and prostaglandins in white fat cells from hamsters treated with pertussis vaccine. FEBS Lett. 1981;126:306-8.

  20. Hazeki O, Ui M. Modification by islet-activating protein of receptor-mediated regulation of cyclic AMP accumulation in isolated rat heart cells. J Biol Chem. 1981;256:2856-62.

  21. Sekura RD. Pertussis toxin: a tool for studying the regulation of adenylate cyclase. Methods Enzymol. 1985;109:558-66.

  22. García-Sáinz JA, Ruiz-Puente J, Jiménez-Paredes J, et al. Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation. Vaccine. 1985;3:23-6.

  23. García-Sáinz JA, Romero-Ávila MT, Ruiz-Arriaga A, et al. Characterization and detoxification of an easily prepared acellular pertussis vaccine. Antigenic role of the A protomer of pertussis toxin. Vaccine. 1992;10:341-4.

  24. García-Sáinz JA. Mecanismo celular de acción de la toxina pertussis. En: Paredes O, Estrada S, editores. Descubrimientos y aportaciones científicas y humanísticas mexicanas en el siglo XX. Ciudad de México: Fondo de Cultura Económica; 2008. p. 291-300.

  25. Escotto-Velázquez J. Semblanza del Dr. Eduardo Liciaga. Revista Médica del Hospital General de México. 1999;62:237-9.

  26. Lefkowitz RJ. A brief history of G-protein coupled receptors (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52;6366-78.

  27. García-Sáinz JA. Robert Lefkowitz y Brian Kobilka: premios Nobel 2012. Revista de la Facultad de Medicina. 2013;56:59-63.

  28. García-Sáinz JA. El Premio Nobel de Química 2012: Lefkowtiz y Kobilka. Educación Química. 2013;24:79-81.

  29. Fredriksson R, Schioth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol. 2005;67:1414-25.

  30. Fredriksson R, Lagerstrom MC, Lundin LG, et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-72.

  31. Kobilka B. The structural basis of G-protein-coupled receptor signaling (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52:6380-8.

  32. García-Sáinz JA, Torres-Padilla ME. Modulation of basal intracellular calcium by inverse agonists and phorbol myristate acetate in rat-1 fibroblasts stably expressing alpha1d-adrenoceptors. FEBS Lett. 1999;443:277-81.

  33. Ziani K, Gisbert R, Noguera MA, et al. Modulatory role of a constitutively active population of alpha(1D)-adrenoceptors in conductance arteries. Am J Physiol Heart Circ Physiol. 2002;282:H475-81.

  34. Gisbert R, Ziani K, Miquel R, et al. Pathological role of a constitutively active population of alpha(1D)-adrenoceptors in arteries of spontaneously hypertensive rats. Br J Pharmacol. 2002;135:206-16.

  35. Villalobos-Molina R, Ibarra M. Vascular alpha 1D-adrenoceptors: are they related to hypertension? Arch Med Res. 1999;30:347-52.

  36. Villalobos-Molina R, López-Guerrero JJ, Ibarra M. Functional evidence of alpha1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. Br J Pharmacol. 1999;126:1534-6.

  37. Kenakin T. New bull’s-eyes for drugs. Sci Am. 2005;293:50-7.

  38. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci. 2007;28:407-15.

  39. Kenakin TP. A pharmacology primer: theory, applications, and methods. Amsterdam: Elsevier Academic Press; 2009.

  40. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883-97.

  41. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 2011;108:751-6.

  42. Tsien RY. The green fluorescent protein. Annu Rev Biochem. 1998;67:509-44.

  43. Castillo-Badillo JA, Cabrera-Wrooman A, García-Sáinz JA. Visualizing G protein-coupled receptors in action through confocal microscopy techniques. Arch Med Res. 2014;45:283-93.

  44. Castillo-Badillo JA, Sánchez-Reyes OB, Alfonzo-Méndez MA, et al. Alpha1B- adrenergic receptors differentially associate with Rab proteins during homologous and heterologous desensitization. PLoS One. 2015;10:e0121165.

  45. Alfonzo-Méndez MA, Hernández-Espinosa DA, Carmona-Rosas G, et al. Protein kinase C activation promotes alpha1B-adrenoceptor internalization and late endosome trafficking through Rab9 interaction. Role in heterologous desensitization. Mol Pharmacol. 2017;91:296-306.

  46. Salahpour A, Espinoza S, Masri B, et al. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front Endocrinol (Lausanne). 2012;3:105.

  47. Salahpour A, Masri B. Experimental challenge to a ‘rigorous’ BRET analysis of GPCR oligomerization. Nat Methods. 2007;4:599-600; author reply 1.

  48. Shrestha D, Jenei A, Nagy P, et al. Understanding FRET as a research tool for cellular studies. Int J Mol Sci. 2015;16:6718-56.




2020     |     www.medigraphic.com